Buy Cagrilintide Peptide in Australia
Buy cagrilintide in Australia from Macropus Peptides in 5mg and 10mg vials. Cagrilintide is a long-acting amylin analogue: a modified version of amylin, the hormone released alongside insulin from the pancreas, engineered to resist breakdown and to stay active for about a week. It acts on amylin and calcitonin receptors, a separate pathway from the GLP-1 class, which makes it a key compound in metabolic research and in studies that pair amylin and incretin signalling. Each vial holds research-grade lyophilised powder, sealed and labelled with compound, strength, lot number and storage temperature, with a certificate of analysis for every lot. The 10mg vial is priced and ready to order, and the 5mg vial is quoted on request. Add bacteriostatic water to the same order and your parcel is dispatched from local Australian stock to any address in the country. For in-vitro laboratory research only, to buyers aged 18 and over; not for human or veterinary use.
| Compound | Cagrilintide |
|---|---|
| Amount | 10 mg |
| Form | Lyophilised powder |
| Category | Metabolic research |
| Storage | -20 °C, protect from light |
| Testing | HPLC purity and mass spectrometry identity, every batch |
| Certificate of analysis | Available for every lot, matched to the lot number on the label |
Cagrilintide 10mg vial
Enter the diluent volume added to this vial to see the solution concentration. Laboratory calculation only, not dosing guidance.
Buy Cagrilintide Australia: 5mg and 10mg Vials
Macropus Peptides supplies this amylin analogue in two vial sizes, 10mg at a listed price and 5mg on quote, as research-grade lyophilised peptide for metabolic laboratories. It belongs to our metabolic research range next to the incretin-class peptides it is most often studied with, and both sizes come from one controlled supply.
What is cagrilintide: a long-acting amylin analogue
Amylin is a 37 amino acid hormone made by the beta cells of the pancreas and released together with insulin after a meal. It slows the rate at which the stomach empties, dampens the glucagon surge after eating and signals fullness to the brainstem. Native human amylin is a poor research tool on its own: it clumps into fibrils in solution and is cleared within minutes. Cagrilintide was engineered to solve both problems. Its sequence is based on human amylin with changes that stop it aggregating, and a fatty acid side chain lets it bind albumin in the blood, stretching its half-life to about a week. Earlier amylin analogues were short-acting and needed several administrations a day, so this long-acting design is what brought the amylin pathway back into mainstream metabolic research.
How the amylin cagrilintide peptide works in research
Amylin receptors are unusual. Each one is a calcitonin receptor paired with a receptor activity-modifying protein, and different pairings give the three amylin receptor subtypes. This analogue switches on all three amylin receptor subtypes and the plain calcitonin receptor as well, earning it the label of a non-selective amylin and calcitonin receptor agonist. The signals it drives act largely in the brainstem, a different route from the GLP-1 receptor used by the incretin peptides. Laboratories use it to study satiety signalling and gastric emptying through the amylin pathway, and to test how that pathway combines with GLP-1, GIP and glucagon receptor agonists.
Cagrilintide research: what the studies show
The design and pharmacology of the peptide appeared in a 2021 Journal of Medicinal Chemistry paper, covering how the amylin sequence was modified and acylated and how the analogue behaved in cell and animal studies. The same year, The Lancet published a phase 2 trial of the peptide on its own and a phase 1b trial combining it with semaglutide. That pairing, developed under the name CagriSema, then moved into phase 3, and a large phase 3 trial of the combination was reported in the New England Journal of Medicine in 2025. Every paper mentioned here is catalogued in our cagrilintide research studies library.
Cagrilintide vial specifications
| Specification | Detail |
|---|---|
| Compound | Cagrilintide |
| Amount | 10 mg |
| Form | Lyophilised powder |
| Category | Metabolic research |
| Storage | -20 °C, protect from light |
A sealed vial holds the freeze-dried amylin analogue as a small white cake. Its label names the compound, its strength, the lot and the storage temperature; ask for the certificate by quoting that lot. Keep the vial in a freezer at -20 °C, away from light, until it is needed.
Cagrilintide price in Australia
| Strength | Price | Price per mg |
|---|---|---|
| Cagrilintide 5mg | Price to confirm | - |
| Cagrilintide 10mg | $169.99 | $17.00 per mg |
The 10mg vial is listed at a fixed Australian dollar price and ships straight away, while the 5mg vial is priced on quote. For studies that run longer than a pilot, the 10mg vial keeps the work on one lot and avoids a second order.
Cagrilintide 10mg: where to buy in Australia
Metabolic laboratories most often start here, and this is the size available at a set price today. Ten milligrams covers method development and a complete study from one lot, which matters for a lipidated peptide whose behaviour in serum-containing media needs to be characterised once and then held constant. Dissolve it in 2 mL for a 5 mg per mL working stock.
Cagrilintide 5mg: the smaller vial
The 5mg vial suits pilot work, a single receptor assay or a first look at how the peptide behaves in a new system. It is quoted on request. Half as much diluent, 1 mL, brings this vial to that same 5 mg per mL strength.
Best place to buy cagrilintide Australia
- Both vial sizes of this amylin analogue drawn from a single controlled supply
- Set pricing for 10mg, individual quotes for 5mg
- Lot number on every label, linked to a batch certificate of analysis
- Held in Australia and shipped from Australian stock, with no customs delays
- Related incretin peptides and diluents in the same order
How to buy cagrilintide online
- Pick the 10mg vial, or ask for a quote on the 5mg size
- Choose a quantity and place the vials in your cart
- Include bacteriostatic water if you need a diluent
- Complete payment and confirm the order is adult laboratory research
- Keep a record of the lot and request the matching certificate
Cagrilintide reconstitution and calculator
Type any diluent volume into the listing's concentration calculator and it reports the concentration of the stock in both milligrams and micrograms. Because the peptide carries a fatty acid chain, it should be dissolved gently: run bacteriostatic water down the inside of the glass and roll the vial slowly rather than shaking it, which can cause foaming and aggregation. Once dissolved, keep the solution refrigerated and out of the freezer, and use it within the window your protocol sets.
Is cagrilintide available in Australia
Australian research laboratories may buy it as bench material, the sole basis on which we sell it. Neither the peptide alone nor any combination containing it holds ARTG registration, which rules out supply for people or animals. The TGA revises the Poisons Standard periodically, so review your organisation's scheduling obligations before placing an order.
Cagrilintide for sale Australia wide
Orders leave our Australian facility for every state and territory, packed with the vial upright and the closure protected. Because it works through the amylin pathway, laboratories often study it next to incretin-class compounds such as Retatrutide, Mazdutide and Survodutide. The full metabolic research range is listed alongside.
References
- Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry. 2021.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. 2021.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025.
Scientific content compiled from the peer-reviewed literature above by the Macropus Peptides technical team. Information is provided for research reference only.